SANEMUS is supporting a diagnostics start-up focused on the identification and characterization of circulating tumor cells (CTC) in finding new investors. The start-up has developed a patent-protected innovative diagnostic system, which is able to identify all CTCs with higher sensitivity and specificity and faster throughput compared to current systems on the market. The address of first VCs  has occured, talks with interested parties are on-going to close the Series A in Q1/Q2 2018. If you are interested in participating, please contact us.